Consolidated Portfolio Review Corp Buys New Holdings in Stryker Corporation (NYSE:SYK)

Consolidated Portfolio Review Corp purchased a new position in shares of Stryker Corporation (NYSE:SYK) in the 1st quarter, Holdings Channel reports. The firm purchased 622 shares of the medical technology company’s stock, valued at approximately $231,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Elefante Mark B purchased a new position in Stryker in the fourth quarter valued at approximately $337,000. Mogy Joel R Investment Counsel Inc. boosted its holdings in shares of Stryker by 3.4% in the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company’s stock valued at $36,561,000 after buying an additional 3,218 shares in the last quarter. Ferguson Wellman Capital Management Inc. grew its position in shares of Stryker by 1.9% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company’s stock valued at $65,096,000 after buying an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in Stryker during the 1st quarter worth $1,840,000. Finally, Metis Global Partners LLC lifted its position in Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock valued at $6,064,000 after acquiring an additional 1,561 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 1.5%

Shares of SYK opened at $392.36 on Thursday. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $149.76 billion, a P/E ratio of 53.02, a PEG ratio of 2.91 and a beta of 0.91. The firm’s 50-day moving average is $377.18 and its two-hundred day moving average is $375.31.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.50 earnings per share. On average, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker’s payout ratio is currently 45.41%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Evercore ISI lowered their target price on shares of Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Roth Mkm lifted their target price on shares of Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. Finally, BTIG Research set a $403.00 price objective on Stryker and gave the company a “buy” rating in a research note on Monday, April 14th. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $427.30.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.